Patient info Open main menu

Palforzia 20 mg oral powder in capsules for Opening – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) ▼ Additional monitoring Details

Medicine strength:
20 mg
Similar medicines:

Patient leaflet - Palforzia 20 mg oral powder in capsules for Opening

1. What PALFORZIA is and what it is used for

PALFORZIA contains peanut protein from defatted powder of peanut seed. It belongs to a class of medicines called food allergens. It is a treatment for people who are allergic to peanuts (Arachis hypogaea L.).

become adults whilst on treatment.

PALFORZIA works in people with peanut allergy by gradually increasing the body’s ability to tolerate small amounts of peanut (desensitisation). PALFORZIA can help reduce the severity of allergic reactions after coming into contact with peanut.

PALFORZIA is not effective against any other nut or food allergies.

You must continue to strictly avoid eating peanuts while taking PALFORZIA.

2. What you need to know before you take PALFORZIA

Do not take PALFORZIA

Warnings and precautions

Talk to your doctor before taking PALFORZIA and tell your doctor about any medical conditions that you have.

You must not take any peanut or peanut containing food in your diet whilst taking PALFORZIA.

It is important to keep a record of the batch number of your PALFORZIA. So, every time you get a new package of PALFORZIA, note down the date and the batch number (which is on the packaging

PALFORZIA does not treat the symptoms of peanut allergy and you must not take PALFORZIA during an allergic reaction.

Your doctor will advise the best time to start treatment depending on any medical conditions that you have.

PALFORZIA contains the substance that patients with peanut allergy react to. Allergic reactions to

after taking a PALFORZIA dose and are usually mild or moderate but ocasionally can be severe.

Stop taking PALFORZIA and get medical treatment straight away if you have any of the following symptoms:

go away or worsens

mouth to the stomach (oesophagus)

There are actions you should take to avoid some of these factors from affecting you. These factors

for advice on what to do about these.

allergic reactions during any of these.

times in case you have a severe allergic reaction. Your doctor will tell you how to recognise an allergic reaction and teach you when and how to use the adrenaline. Talk to your doctor and read the

If you use adrenaline, do not take any further doses of PALFORZIA and seek emergency medical care immediately afterwards.

Desensitisation to peanut with PALFORZIA takes time. The ability to tolerate gradually increasing

and after at least 3 months of maintenance therapy and this continues to improve over time.

can lead to an increased risk of allergic reactions.

PALFORZIA treatment may not work in all patients.

Children and adolescents

adults whilst on treatment.

Do not give this medicine to children aged less than 4 years because it is not known if PALFORZIA is safe and effective in this age group.

Other medicines and PALFORZIA

Tell your doctor if you are taking, have recently taken, or might take any other medicines.

PALFORZIA with food, drink and alcohol

likelihood of an allergic reaction.

Pregnancy, breast-feeding and fertility

Do not start treatment with PALFORZIA if you are pregnant or planning to become pregnant.

your doctor for advice before taking this medicine.

Driving and using machines

reactions have gone away before driving, cycling, or using machinery.

3. How to take PALFORZIA

sure.

How should I take PALFORZIA?

Dosing

maintenance. You must complete these treatment phases in the order that your doctor has prescribed.

precise way. During the maintenance phase, you take the same dose of PALFORZIA each day.

You should take PALFORZIA every day to maintain your level of desensitisation to peanuts.

Tell your doctor on the day of each clinic visit if you are feeling unwell or if you feel your asthma is less controlled.

Initial dose escalation

If you tolerate the initial doseescalation phase, you will be asked to return to your doctor’s clinic on

increasing to PALFORZIA 300 mg (level 11).

Daily dose Dose level Presentation of dose

3 mg

o you by your doctor in a clinic. If you tolerate the

PALFORZIA at a 300 mg dose every day as maintenance therapy.

Preparation for use

PALFORZIA is available either in capsules or sachets. Empty the powder from PALFORZIA capsules or sachets.

Do not swallow PALFORZIA capsules.

Open the daily dose of PALFORZIA.

thumb. Tap the ends of each half capsule to make sure that all the powder is emptied.

upside down over a bowl with soft food and tap the sachet to make sure that all the powder is emptied.

Empty the full dose of PALFORZIA oral powder on to a small amount of soft food to which you are

full dose.

throw it away and prepare a new dose.

Handling instructions

Do not breathe in PALFORZIA powder as this could cause breathing problems (worsening of asthma) or cause an allergic reaction.

remaining capsules or sachets from that pack (see section 5) before starting on a new level. This

Dosing instructions

Take PALFORZIA at about the same time every day with food, preferably as part of your evening meal. Do not take this medicine on an empty stomach.

Do not take PALFORZIA at home on the days that you visit your doctor for assessment as your doctor will give you PALFORZIA on these days.

about 1 hour afterwards for any symptoms of an allergic reaction.

Do not have a hot bath or shower just before or for 3 hours after taking PALFORZIA.

sweating and your heart is beating fast, do not take PALFORZIA until you have cooled down and your heart rate (pulse) has returned to normal.

Do not take more than your individual total daily dose according to your current dose level of PALFORZIA in a single day.

If you take more PALFORZIA than you should

Taking PALFORZIA at doses more than those recommended increases the risk of allergic reactions.

instructed by your doctor and then contact a doctor immediately.

If you forget to take PALFORZIA

Do not take a double dose to make up for a forgotten dose.

increase your risk of allergic reactions.

If you miss your dose of PALFORZIA for 3 days in a row or longer, stop taking PALFORZIA and contact your doctor for advice on how to start your treatment again.

If you stop taking PALFORZIA

Stopping PALFORZIA may cause you to lose the peanut tolerance you have built up and increase your risk of allergic reactions.

If you have any further questions on the use of this medicine, ask your doctor.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Important side effects

following symptoms, stop taking PALFORZIA, treat the reaction according to any instructions previously provided by your doctor, and then contact a doctor immediately.

PALFORZIA can cause problems with the stomach and digestive system including eosinophilic oesophagitis. This is a condition that affects the passage between the mouth and the stomach and affects up to 1 in 1,000 people. Symptoms of eosinophilic oesophagitis can include:

If you have these symptoms persistently, contact a doctor.

Other side effects

Very common (may affect up to 1 in 10 people)

Common (may affect up to 1 in 100 people)

Allergic reactions may affect different parts of the body as follows:

irritation

Stomach related: stomach pain, feeling sick, vomiting

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store PALFORZIA

Keep this medicine out of the sight and reach of children.

date which is stated on the carton and the blister or sachet .

Store below

Do not use this medicine if you notice any hard lumps of powder that do not easily fall apart or if the powder is discoloured.

Do not throw away any medicines via household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What PALFORZIA contains

The active substance is peanut protein from defatted powder of peanut (Arachis hypogaea L.) seed.

The other ingredients are:

PALFORZIA 0.5 mg, 1 mg, 10 mg oral powder in capsules for opening Partially pregelatinised maize starch, microcrystalline cellulose, colloidal anhydrous silica, magnesium stearate

PALFORZIA 100 mg oral powder in capsules for opening

cellulose, colloidal anhydrous silica, magnesium stearate

PALFORZIA 300 mg oral powder in sachet

cellulose, colloidal anhydrous silica, magnesium stearate

What PALFORZIA looks like and contents of the pack

to beige oral powder in capsule for opening or sachet.

Initial dose escalation (see section 3)

Each carton contains 13

Name/Capsule or sachet strength Pack contents by dose level (daily dose)

PALFORZIA 1 mg oral powder in capsules for opening

Level 1 (3 mg daily):

Level 2 (6 mg daily):

PALFORZIA 10 mg

PALFORZIA 1 mg oral powder in capsules for opening

Level 3 (12 mg daily):

oral powder in capsules for opening

Level 4 (20 mg daily):

Level 5 (40 mg daily):

Level 6 (80 mg daily):

PALFORZIA 100 mg oral powder in capsules for opening

Level 9 (200 mg daily):

PALFORZIA 100 mg oral powder in capsules for opening

Level 7 (120 mg daily):

Level 8 (160 mg daily):

Level 10 (240 mg daily):

PALFORZIA 300 mg oral powder in sachet

Level 11 (300 mg daily):

15 sachets (300 mg sachet)

Each carton contains 30 sachets of 300 mg.

Marketing Authorisation Holder

STALLERGENES

6 rue Alexis de Tocqueville

92160 Antony

France

Manufacturer

For

Authorisation Holder:

STALLERGENES

Tel: +44 (0)800 0487 217

This leaflet was last revised in February 2025.

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PLGB 04534/0022

Last revision stated in the text: February 2025 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Palforzia 20 mg oral powder in capsules for Opening

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Peanut protein (as defatted powder of Arachis hypogaea L., semen [peanuts])
Strength 20 mg
Pharmaceutical form Oral powder
PALFORZIA 20 mg oral powder in capsules for opening
Oral powder in white opaque hard capsules (23 x 9 mm)
How is it taken Oral
Excipients PALFORZIA 20 mg oral powder in capsules for opening, Microcrystalline cellulose, Partially pre-gelatinised maize starch, Colloidal anhydrous silica, Magnesium stearate, Capsules for opening contain hydroxypropyl methylcellulose (HPMC)., 20 mg capsule (white), Hydroxypropyl methylcellulose, Titanium dioxide (E171), Grey TEK SW 5014 (ink)
Pack sizes 16 capsule, 32 capsule, 48 capsule
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 2 years – Initial dose escalation pack
3 years – All packs except initial dose escalation pack
After mixing a daily dose of PALFORZIA with age-appropriate soft-food, the entire volume of the prepared mixture should be consumed promptly, but if necessary, can be refrigerated for up to 8 hours.
Storage Store below 25°C.
Drug group (ATC) Allergen extracts, food
  1. V Various drug classes
    1. V01 Allergens
      1. V01A Allergens
        1. V01AA Allergen extracts
          1. V01AA08 Food allergenic extracts
Additional monitoring Yes ▼ – new safety information is collected quickly. Report any side effect to the Yellow Card scheme.
Marketing authorisation PLGB 04534/0022 (first authorised 1 January 2021)
Marketing authorisation holder STALLERGENES

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.